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1. Disease characteristics 
1.1 Name of the Disease (Synonyms): 
Inherited optic neuropathies can be caused by mitochondrial DNA (mtDNA) variants as in Leber 
hereditary optic neuropathy (Table 1) or by variants in nuclear-encoded genes (Table 2). 
 
1.2 OMIM# of the Disease: 
Please refer to Table 1 and Table 2. 
 
1.3 Name of the Analysed Genes or DNA/Chromosome segments: 
1.3.1 Core genes (irrespective if being tested by Sanger sequencing or next-generation sequencing) 
Core disease-causing genes have been listed in Table 1 and Table 2 and marked with § symbol. 
 
1.3.2 Additional genes (if tested by next-generation sequencing, including whole-exome/genome 
sequencing and panel sequencing) 
Additional disease-causing genes have been listed in Table 1 and Table 2. 
 
Table 1. Mitochondrial DNA (mtDNA) variants identified in patients with LHON. 
Name of the 
disease OMIM# of the disease Variant 
Associated 
gene(s) 
OMIM# of 
associated 
gene(s) 
Leber hereditary 
optic neuropathy 
(LHON) 
535000 
m.11778G>A⃰ 
m.11696G>A 
m.11253T>C 
MTND4§ 516003 
 
 
m.14484T>C⃰ 
m.14325T>C 
m.14568C>T 
m.14459G>Aa 
m.14729G>A 
m.14482C>Ga  
m.14482C>Aa 
m.14495A>Ga 
m.14498C>T 
m.14568C>Ta 
m.14596A>T 
MTND6§ 516006 
 
 
m.3460G>A⃰ 
m.3376G>A 
m.3635G>Aa 
m.3697G>A 
m.3700G>Aa 
m.3733G>Aa 
m.4025C>T 
m.4160T>C 
m.4171C>Aa 
MTND1§ 516000 
  m.4640C>A 
m.5244G>A MTND2 516001 
  m.10237T>C MTND3 516002 
  m.10663T>Ca MTND4L 516004 
  m.12811T>C 
m.12848C>T 
m.13637A>G 
m.13730G>A 
MTND5 516005 
  m.9101T>C MTATP6 516060 
  m.9804G>A MTCO3 516050 
  m.14831G>A MTCYB 516020 
Variants were assigned according to the human mitochondrial genome reference sequence 
NC_012920.1.
⃰ The three most common mtDNA variants that cause LHON have been highlighted in bold.  
§ Core genes. 
a These mtDNA variants affecting function. They have been identified in ≥ 2 independent LHON 
pedigrees and show segregation with affected disease status. 
The remaining putative LHON variants have been found in singleton cases or in a single family, and 
additional evidence is required before pathogenicity can be irrefutably ascribed.  
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1.4 Mutational Spectrum: 
Inherited optic neuropathies are a clinically heterogeneous group of disorders that can be caused by 
variants in both the nuclear and mitochondrial genomes. MtDNA variants (Table 1) show strict 
maternal inheritance whereas nuclear variants can be inherited in dominant, recessive or X-linked 
patterns of inheritance (Table 2). Rarely, de novo variants have also been reported. 
 
The two most common inherited optic neuropathies are autosomal dominant optic atrophy (DOA) 
secondary to variants in the OPA1 gene (OMIM 165500) and LHON (OMIM 535000). LHON is caused 
by mtDNA variants and three so-called primary variants, m.3460G>A, m.11778G>A, and 
m.14484T>C, account for ~ 90% of all cases. These variants change amino acid sequence in NADH-
ubiquinone oxidoreductase protein (EC:1.6.5.3) (www.uniprot.org).  The mtDNA variant is 
heteroplasmic in 10-15% of LHON carriers. Optic atrophy has also been reported as a variable clinical 
feature in patients with other classical mitochondrial syndromes, for example, maternally inherited 
Leigh syndrome (MILS); myoclonic epilepsy associated with ragged-red fibers (MERRF); the 
syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP); mitochondrial myopathy, 
encephalopathy, lactic acidosis and stroke-like episodes (MELAS); mitochondrial neurogastrointestinal 
encephalopathy (MNGIE); chronic progressive external ophthalmoplegia (CPEO); and the Kearns-
Sayre syndrome (KSS).1,2 
 
The list of nuclear-encoded genes that are known to cause optic atrophy is rapidly expanding. For 
some genes, for example, OPA1 and WFS1, optic atrophy is a defining phenotypic manifestation, 
whereas for others, it is a minor clinical feature observed in only some carriers. Greater access to 
molecular genetic testing has expanded the phenotype associated with specific disease-causing 
genes and we have used a broad classification based on whether the patient exhibits isolated or 
syndromic optic atrophy (Table 2). The disease-causing variants for DOA can be found in LOVD 
database at https://databases.lovd.nl/shared/individuals/OPA1 (Accessed February 28, 2018). A 
database for LHON mtDNA variants is publicly available through MITOMAP at 
https://www.mitomap.org/foswiki/bin/view/MITOMAP/MutationsLHON (Accessed February 28, 2018). 
A clinical utility card has previously been published for Wolfram syndrome.3 
 
1.5 Analytical Validation 
In a suspected case of LHON, targeted screening of the three common mtDNA variants (m.3460G>A, 
m.11778G>A, and m.14484T>C) by bi-directional fluorescent Sanger sequencing is the routine 
practice. If negative, sequencing of the complex I subunit genes (MTND1, MTND2, MTND3, MTND4, 
MTND4L, MTND5 and MTND6) or sequencing of entire mitochondrial genome can be considered if 
there is a high index of clinical suspicion and the facilities are available.4 If indicated, pyrosequencing 
or next-generation sequencing (NGS) can be used to estimate the level of heteroplasmy.5  
 
The screening method for patients with an inherited optic atrophy that is not thought to have a 
mitochondrial genetic basis will vary depending on the facilities available locally. Bi-directional 
fluorescent Sanger sequencing of coding exons including intron-exon boundaries of a particular gene 
remains the most widely used method, especially in a patient with a clear-cut phenotype. This can be 
complemented with multiplex ligation-dependent probe amplification (MLPA) dosage analysis to detect 
copy number variants. With the advent of NGS technology, clinical exome panels are now being 
increasingly offered by diagnostic laboratories, allowing for a large number of optic atrophy genes to 
be screened faster and more cost effectively. Analyses of known positive and negative control 
samples are required for validation of any diagnostic genetic test procedure. Diagnostic testing must 
be carried out within a laboratory environment working to standards compliant with the ISO 15189. 
Causative variants found with NGS should be verified using Sanger sequencing or other methods, for 
further details, see the Eurogentest Guideline (https://www.genetests.org). 
 
1.6 Estimated frequency of the disease (Incidence at birth (‘birth prevalence’) or 
population prevalence) 
 
Inherited optic neuropathies have an estimated prevalence of 1 in 10,000 in the general population.6 
The prevalence of LHON (OMIM 535000) varied between 1 in 31,000 and 1 in 54,000 in different 
population-based epidemiological surveys in Northern Europe.1,2,7,8 The incidence has recently been 
reported at 1 in 1,000,000 in the Japanese population.9 The prevalence of OPA1 variants has been 
estimated at 1 in 25,000 in the United Kingdom compared with a higher figure of 1 in 10,000 in 
Denmark, which could be due to a founder effect.6,10,11  
 
1.7 Diagnostic Setting: 
 Yes. No. 
A. (Differential) diagnostics    
B. Predictive Testing    
C. Risk assessment in Relatives    
D. Prenatal    
 
2. Test characteristics 
 
 
2.1 Analytical Sensitivity 
(proportion of positive tests if the genotype is present)  
2.1.1 If tested by conventional Sanger sequencing 
Less than 100% 
The proportion is likely to be less than 100%.12 Loss of sensitivity may be due to the location of 
primers in sequences containing single nucleotide variants (SNVs) or rare variants, which results in 
the preferential amplification of one allele (allele dropout). In addition, direct Sanger sequencing is 
likely to fail to detect copy number loss/gains. A supplementary deletion/duplication diagnostic test 
should be performed for genes with a known proportion of large genomic deletions/duplications. 
 
For homoplasmic mtDNA variants, analytical sensitivity of real-time PCR, RFLP analysis and Sanger 
sequencing of the three common LHON variants approach 100%. Heteroplasmy, which is present in 
10-15% of LHON carriers, does not influence the sensitivity of molecular genetic testing for LHON 
because affected individuals generally have more than 70% of the mutated mtDNA in leukocytes, 
which is easily detected by these standard techniques.13 
 
2.1.2 If tested by next-generation sequencing 
Less than 100% 
Analytical sensitivity of the NGS panels for single nucleotide variant detection is estimated to be 
97.9%.12 Loss of sensitivity may be due to incomplete coverage of regions of interest, including low 
complexity regions and GC-rich regions intractable to PCR enrichment. A diagnostic test for large-
scale genomic rearrangements, such as duplications and deletions, should be incorporated into the 
analysis pipeline to help improve analytical sensitivity. 
 
2.2 Analytical Specificity 
(proportion of negative tests if the genotype is not present)  
2.2.1 If tested by conventional Sanger sequencing 
Nearly 100%.  
False positives may, at the most, arise due to misinterpretation of rare polymorphic variants. 
 
2.2.2 If tested by next-generation sequencing 
Nearly 100%.  
False positives may, at the most, arise due to misinterpretation of rare polymorphic variants. However, 
the use of the ACMG (American College of Medical Genetics) standards and guidelines for the 
interpretation of sequence variants may reduce the risk of false positive test results. 
 
2.3 Clinical Sensitivity 
(proportion of positive tests if the disease is present) 
The clinical sensitivity can be dependent on variable factors such as age or family history. In such 
cases a general statement should be given, even if a quantification can only be made case by case. 
2.3.1 If tested by conventional Sanger sequencing 
LHON ~ 90%.  
LHON is characterised by bilateral, painless, subacute, central vision loss. The visual prognosis is 
poor and the majority of patients are registered legally blind.14 Nevertheless, childhood onset LHON 
has a more variable pattern of visual loss and a relatively better visual prognosis.15 LHON has a 
distinct phenotype and if the diagnostic work-up has excluded acquired causes of a bilateral optic 
neuropathy, the clinical sensitivity of genetic testing for the three common mtDNA LHON variants 
(m.3460G>A, m.11778G>A, and m.14484T>C) is likely to be ~ 90%. Additional mtDNA sequencing 
will further improve the clinical sensitivity. 
 
DOA 65-75%.  
For patients with a clinical diagnosis of DOA and a positive family history, the clinical sensitivity of 
OPA1 screening is reported to be 65-75%.16,17 In more heterogeneous cohorts of patients with a 
suspected inherited optic neuropathy, clinical sensitivities are reduced to 8.6-30% for OPA1 screening 
and < 1.4% for OPA3 screening, influenced by factors such as age, family history and the presence of 
additional clinical deficits besides optic atrophy.16–18 
 
2.3.2 If tested by next-generation sequencing 
No published data. Although extensive data is as yet unavailable, NGS gene panel testing for clinically 
confirmed cases of LHON and DOA is expected to have clinical sensitivity at least equivalent to that of 
direct Sanger sequencing. Furthermore, it is expected that NGS panel testing will improve clinical 
sensitivity in more heterogeneous patient cohorts with suspected inherited optic atrophy due to its 
ability to capture a greater number of candidate genes in a single test and to identify potentially 
pathogenic variants in rarer disease-causing genes. 
 
2.4 Clinical Specificity (proportion of negative tests if the disease is not present) 
The clinical specificity can be dependent on variable factors such as age or family history. In such 
cases a general statement should be given, even if a quantification can only be made case by case. 
2.4.1 If tested by conventional Sanger sequencing 
As LHON is characterised by incomplete penetrance and the prevalence of the pathogenic mtDNA 
variants has been estimated at 1 in 200 in the general population, these factors can lower the clinical 
specificity.19 The clinical specificity for nuclear-encoded optic atrophy genes will be influenced by the 
prevalence of mutant alleles in the population, disease penetrance and the age of onset of clinical 
features.19  
 
2.4.2 If tested by next-generation sequencing 
See 2.4.1 
 
2.5 Positive clinical predictive value (life time risk to develop the disease if the test is 
positive) 
LHON is characterized by incomplete penetrance and a predominance for male LHON carriers to lose 
vision. The penetrance varies widely, both within and between families, but on average, ~ 50% of male 
carriers and ~ 10% of female carriers experience visual loss with a peak age of onset in the third 
decade of life.  The majority of OPA1 variant carriers show evidence of clinical or subclinical optic 
nerve involvement. There is limited published data on the positive clinical predictive value for other 
nuclear-encoded optic atrophy genes. 
 
2.6 Negative clinical predictive value (Probability not to develop the disease if the test 
is negative). 
Assume an increased risk based on family history for a non-affected person. Allelic and locus 
heterogeneity may need to be considered. 
Index case in that family had been tested: 
If a non-affected relative is negative for the disease-causing variant identified in the index case, there 
is no increased risk, except for that related to the prevalence of other disease-causing genes or loci in 
the general population. 
 
Index case in that family had not been tested: 
Not known. 
3. Clinical Utility 
3.1 (Differential) diagnostics: The tested person is clinically affected 
       (To be answered if in 1.9 "A" was marked) 
3.1.1 Can a diagnosis be made other than through a genetic test? 
 
No.  (continue with 3.1.4) 
Yes,  
 clinically.   
 imaging .   
 endoscopy.   
 biochemistry.   
 electrophysiology.  
other (please describe):       
 
3.1.2 Describe the burden of alternative diagnostic methods to the patient 
Irrespective of the availability or decision to proceed with genetic testing, a patient with a suspected 
diagnosis of an inherited optic neuropathy will undergo a comprehensive neuro-ophthalmological 
evaluation, including determination of any relevant family history and appropriate ocular investigations 
such as optical coherence tomography (OCT) imaging20–23 and visual electrophysiology if 
relevant.1,24,25 MRI neuroimaging is also indicated to exclude lesions of the anterior visual pathways as 
the underlying cause of the optic neuropathy.  
 
3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?  
A diagnosis of an inherited optic neuropathy can usually be made based on the clinical and 
ophthalmological findings, following exclusion of other possible acquired causes of an optic 
neuropathy. However, confirmatory molecular genetic testing is advisable as a positive result can have 
important implications for genetic counselling, family planning and possible treatment options. 
 
3.1.4 Will disease management be influenced by the result of a genetic test? 
No.  
 
Yes.  
 Therapy (please describe)  There are limited treatment options for inherited optic 
neuropathies. A subgroup of patients with LHON can benefit 
partially from early treatment with idebenone, which has been 
approved by the European Medicine Agency under 
exceptional circumstances.26 Experimental trials of 
neuroprotective drugs and gene therapy strategies are 
currently ongoing.27–32 
 Prognosis (please describe)  LHON has a relatively poor visual prognosis. The 
m.14484T>C mtDNA variant carries the highest likelihood of 
spontaneous visual recovery. The risk of visual loss for a 
LHON carrier is influenced by age and sex, but it is not 
possible to accurately predict risk at the individual level. 
There is a wide variability in disease severity for nuclear-
encoded genes that cause optic atrophy. Data on genotype-
phenotype correlations is also limited, especially for relatively 
rare genes and syndromic manifestations. 
 Management (please describe) The management of patients with inherited optic neuropathies 
remains largely supportive.33 Extraocular complications in 
patients with syndromic optic atrophy, such as diabetes 
mellitus, peripheral neuropathy, epilepsy and deafness, 
should be managed as part of a multidisciplinary team to 
prevent or minimise additional comorbidities. Visual 
rehabilitation plays an important role in improving the 
patient’s quality of life. Supportive measures for those with 
sight impairment include involvement of social services. 
 
3.2 Predictive Setting: The tested person is clinically unaffected but carries an 
increased risk based on family history 
(To be answered if in 1.8 "B" was marked) 
3.2.1 Will the result of a genetic test influence lifestyle and prevention? 
 
If the test result is positive (please describe)  
Idebenone been found to be beneficial in a subgroup of patients with visual loss from LHON treated in 
the acute stage of the disease. Smoking and to a lesser extent, excessive drinking, have been linked 
with an increased risk of visual loss among LHON carriers and appropriate lifestyle as well as family 
planning advice should therefore be provided as part of genetic counselling.1,26,34 There is currently no 
available disease-modifying treatment for optic atrophy caused by nuclear-encoded genes.  
If the test result is negative (please describe)  
If the test results are negative, the diagnosis should be re-evaluated and other causes of optic 
neuropathy should be considered. Negative results may influence choice of career and inform family 
planning. 
3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no genetic 
test has been done (please describe)? 
Overall, inherited optic neuropathies carry a poor visual prognosis. A confirmed diagnosis is therefore 
recommended to allow for appropriate counselling with regards to educational support, career choices 
and family planning. 
 
3.3 Genetic risk assessment in family members of a diseased person 
     (To be answered if in 1.9 "C" was marked) 
 
3.3.1 Does the result of a genetic test resolve the genetic situation in that family? 
Yes. A confirmed molecular diagnosis can help define the genetic risk. MtDNA variants are strictly 
maternally transmitted. The risk of transmission for nuclear-encoded genes will be dictated by the 
mode of inheritance for a particular mutant allele. 
 
3.3.2 Can a genetic test in the index patient save genetic or other tests in family members?  
Yes. A homoplasmic mtDNA variant is expected to be present in all maternally-related family 
members. If the mtDNA variant is heteroplasmic, there can be rapid shifts in heteroplasmy level due to 
the mitochondrial bottleneck effect and carrier testing is recommended, especially in the context of 
family planning and reproductive choices.35 With regards to nuclear-encoded genes, carrier testing 
may be indicated if the variant is thought to have arisen de novo or in possible cases of non-paternity. 
If the genetic result for the index patient is negative, molecular testing for other family members is not 
required. 
 
3.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family 
member? 
Yes. 
 
 
3.4 Prenatal diagnosis 
(To be answered if in 1.9 "D" was marked) 
 
3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis? 
Yes. Due to the complex factors that influence the risk of disease and transmission, reproductive 
choices and prenatal counselling should be provided by a qualified health professional as part of a 
multidisciplinary team. Please refer to reference36 for a comprehensive review of this area of practice. 
 
4. If applicable, further consequences of testing 
Please assume that the result of a genetic test has no immediate medical consequences. Is there any 
evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please 
describe) 
Reaching a confirmed molecular genetic diagnosis for a patient with a clinical diagnosis of an inherited 
optic neuropathy can allow for more informed discussions about the mode of inheritance, recurrence 
risk and disease prognosis. A positive genetic test result will also exclude other possible causes of 
optic neuropathy. 
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1. Name of the Disease (Synonyms): 
LHON, CMT2A2A, HMSN6A, CMT2A2B, HAYOS, optic atrophy with multisystem neurological 
disorder, DCMA syndrome, DOA plus, CPEO, optic atrophy with lethal infantile encephalopathy and 
hypertrophic cardiomyopathy, BEHRS, WFSL, WFS1, WFS2, Bosch-Boonstra-Schaaf optic atrophy 
syndrome, CMT6B, OPA10, FRDA, Type I 3-methylglutaconic aciduria with optic atrophy, SPAX4, 
OPA11, OPA7, EMPF1, SPG55, Alpers type mitochondrial DNA depletion syndrome, SPG7, PEHO, 
optic atrophy with intellectual disability, SPG43, ADOAC, Costeff syndrome, OPA9, OPA2, MTS. 
 
2. OMIM# of the Disease:  
535000, 609260, 601152, 617087, 617183, 252010, 610198, 165500, 125250, 210000, 614296, 
222300, 604928, 615722, 616505, 616732, 258500, 613672, 612989, 614388, 610505, 615035, 
616648, 607259, 605293, 165300, 258501, 610708, 616289, 311050, 304700, 229300, 250950, 
617302, 258450, 260565, 615043 
 
3. Name of the Analysed Genes or DNA/Chromosome Segments: 
MTND4, MTND6, MTND1, MTND2, MTND3, MTND4L, MTND5, MTATP6, MTCO3, MTCYB, MFN2, 
ATAD3A, NDUFS1, DNAJC19, OPA1, WFS1, CISD2, NR2F1, SLC25A46, RTN4IP1, OPA6, MTPAP, 
TNEM126A, DNM1L, TSFM, C12orf65, OPA8, SPG7, AFG3L2, OPA4, OPA3, OPA5, ACO2, OPA2, 
TIMM8A, FXN, AUH, YME1L1, POLG, ZNHIT3, C19orf12 
 
4. OMIM# of the Gene(s): 
516003, 516006, 516000, 516001, 516002, 516004, 516005, 516060, 516050, 516020, 608507, 
612316, 157655, 608977, 605290, 606201, 611507, 132890, 610826, 610502, 258500, 613669, 
612988, 603850, 604723, 613541, 616648, 602783, 104206, 605293, 606580, 610708, 100850, 
311050, 300356, 606829, 600529, 607472, 174763, 604500, 614297 
 
 
 
Review of the analytical and clinical validity as well as of the clinical utility of DNA-based testing for 
variants in the listed gene(s) in  diagnostic,  
      predictive and  
      prenatal settings and for  
      risk assessment in relatives. 
 
